Literature DB >> 2504861

Influence of development, estrogens, and food intake on apolipoprotein A-I, A-II, and E mRNA in rat liver and intestine.

B Staels1, J Auwerx, L Chan, A van Tol, M Rosseneu, G Verhoeven.   

Abstract

UNLABELLED: The influence of development and ethinylestradiol (EE) on apolipoprotein (apo) A-I, A-II, and E mRNA in rat liver and intestine was studied by dot blot hybridization and Northern blot analysis. ApoA-I mRNA levels were maximal in the perinatal period and declined after day 15. An opposite trend was noted for the apoA-II mRNA levels, whereas apoE mRNA remained fairly constant. Liver apoA-I mRNA levels increased after ovariectomy (OVX). A further rise was observed when EE was given at 2000 micrograms/day. When the influence of OVX and EE was controlled for food intake by pair-feeding, OVX still increased hepatic apoA-I mRNA. The rise in liver apoA-I mRNA after EE, however, was no longer significant. Under the same conditions OVX slightly increased intestinal apoA-I mRNA. EE (2000 micrograms/day) decreased intestinal apoA-I mRNA to 80% of the pair-fed controls. Liver apoA-II mRNA levels did not change after OVX when the animals were fed ad libitum, but decreased slightly when the rats were pair-fed. EE caused a dose-dependent decrease in liver apoA-II mRNA, irrespective of food intake. None of these treatments caused any change in liver apoE mRNA levels. Serum apoA-I levels increased upon OVX, while serum apoE did not change. EE provoked a dose-dependent decrease of both apolipoproteins in serum. IN
CONCLUSION: 1) Changes in food intake play an important role in the in vivo effects of estrogens on apolipoprotein mRNA levels. 2) The stimulatory effect of OVX on hepatic apoA-I mRNA as well as the inhibitory effect of EE on hepatic apoA-II mRNA are independent of food intake.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2504861

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  12 in total

1.  Regulation of lipoprotein metabolism by estrogen in inbred strains of mice occurs primarily by posttranscriptional mechanisms.

Authors:  R A Srivastava; E S Krul; R C Lin; G Schonfeld
Journal:  Mol Cell Biochem       Date:  1997-08       Impact factor: 3.396

2.  Effects of Pinus pinaster and Pinus koraiensis seed oil supplementation on lipoprotein metabolism in the rat.

Authors:  G Asset; B Staels; R L Wolff; E Baugé; Z Madj; J C Fruchart; J Dallongeville
Journal:  Lipids       Date:  1999-01       Impact factor: 1.880

Review 3.  Proteinases and myocardial extracellular matrix turnover.

Authors:  S C Tyagi
Journal:  Mol Cell Biochem       Date:  1997-03       Impact factor: 3.396

4.  Regulation of the apolipoprotein E by dietary lipids occurs by transcriptional and post-transcriptional mechanisms.

Authors:  R A Srivastava
Journal:  Mol Cell Biochem       Date:  1996-02-23       Impact factor: 3.396

Review 5.  High density lipoprotein, apolipoprotein A-I, and coronary artery disease.

Authors:  R A Srivastava; N Srivastava
Journal:  Mol Cell Biochem       Date:  2000-06       Impact factor: 3.396

6.  The proximal element of the human apolipoprotein A-II promoter increases the enhancer activity of the distal region.

Authors:  J M Lacorte; E Fourniat; D Pastier; J Chambaz; A Ribeiro; P Cardot
Journal:  Biochem J       Date:  1996-09-01       Impact factor: 3.857

7.  Synergistic interactions between transcription factors control expression of the apolipoprotein AI gene in liver cells.

Authors:  R L Widom; J A Ladias; S Kouidou; S K Karathanasis
Journal:  Mol Cell Biol       Date:  1991-02       Impact factor: 4.272

8.  Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice.

Authors:  L Berthou; N Duverger; F Emmanuel; S Langouët; J Auwerx; A Guillouzo; J C Fruchart; E Rubin; P Denèfle; B Staels; D Branellec
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

9.  A case-control study of non-alcoholic fatty liver disease in breast cancer.

Authors:  Ahmet Bilici; Mustafa Ozguroglu; Ismail Mihmanli; Hande Turna; Ibrahim Adaletli
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

10.  Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.

Authors:  L J Black; M Sato; E R Rowley; D E Magee; A Bekele; D C Williams; G J Cullinan; R Bendele; R F Kauffman; W R Bensch
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.